[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX366122B - Formulaciones de daptomicina y usos de la misma. - Google Patents

Formulaciones de daptomicina y usos de la misma.

Info

Publication number
MX366122B
MX366122B MX2015003164A MX2015003164A MX366122B MX 366122 B MX366122 B MX 366122B MX 2015003164 A MX2015003164 A MX 2015003164A MX 2015003164 A MX2015003164 A MX 2015003164A MX 366122 B MX366122 B MX 366122B
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
daptomycin formulations
methods
lyophilized daptomycin
formulations
Prior art date
Application number
MX2015003164A
Other languages
English (en)
Other versions
MX2015003164A (es
Inventor
Jim Alexiou
Andrew Knill
Noel Norris
Darryl Whittaker
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366122(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of MX2015003164A publication Critical patent/MX2015003164A/es
Publication of MX366122B publication Critical patent/MX366122B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones de daptomicina liofilizada teniendo tiempos de reconstitución mejorados; las formulaciones de daptomicina liofilizada incluyen un aditivo, que puede ser un antioxidante farmacéuticamente aceptable, un ácido orgánico farmacéuticamente aceptable o una sal farmacéuticamente aceptable del mismo, un derivado de glucosa farmacéuticamente aceptable o una sal farmacéuticamente aceptable del mismo; o una combinación de los mismos; también se proporcionan métodos de preparación de las formulaciones de daptomicina liofilizada, y métodos de tratamiento de infecciones bacterianas o prevención de biopelículas por medio del uso de las formulaciones de daptomicina liofilizada.
MX2015003164A 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de la misma. MX366122B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201361839699P 2013-06-26 2013-06-26
PCT/IB2013/002191 WO2014041425A1 (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Publications (2)

Publication Number Publication Date
MX2015003164A MX2015003164A (es) 2015-12-16
MX366122B true MX366122B (es) 2019-06-27

Family

ID=50277707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003164A MX366122B (es) 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de la misma.

Country Status (20)

Country Link
US (4) US9655946B2 (es)
EP (2) EP2895187A4 (es)
AU (2) AU2013316779A1 (es)
BR (1) BR112015005400B1 (es)
CA (1) CA2884484C (es)
CL (1) CL2015000608A1 (es)
CY (1) CY2200004T2 (es)
DE (1) DE13837694T1 (es)
DK (1) DK2895187T1 (es)
ES (1) ES2552754T1 (es)
HK (1) HK1207006A1 (es)
HU (1) HUE13837694T1 (es)
IL (1) IL237652B (es)
MX (1) MX366122B (es)
NZ (3) NZ741342A (es)
SA (1) SA515360129B1 (es)
SG (1) SG11201506113WA (es)
TN (1) TN2015000090A1 (es)
WO (1) WO2014041425A1 (es)
ZA (1) ZA201502310B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
MX366122B (es) * 2012-09-11 2019-06-27 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma.
ES2946600T3 (es) 2016-10-21 2023-07-21 Xellia Pharmaceuticals Aps Formulaciones líquidas de daptomicina
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
CN115243675A (zh) 2020-03-12 2022-10-25 巴克斯特国际公司 含有山梨糖醇和甘露糖醇的组合的达托霉素制剂
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药（中山）有限公司 一种注射用达托霉素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
DK1674107T3 (en) * 1998-09-25 2016-12-19 Cubist Pharmaceuticals Llc Use of daptomycin
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
US8003673B2 (en) * 2005-05-31 2011-08-23 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
JP2013511522A (ja) * 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
TWI606838B (zh) 2009-11-23 2017-12-01 庫比斯特製藥有限責任公司 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
PT2887953T (pt) * 2012-08-23 2018-01-10 Mylan Laboratories Ltd Formulação injetável de daptomicina melhorada
MX366122B (es) * 2012-09-11 2019-06-27 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma.

Also Published As

Publication number Publication date
AU2013316779A1 (en) 2015-04-02
NZ741342A (en) 2019-10-25
BR112015005400B1 (pt) 2022-03-08
WO2014041425A1 (en) 2014-03-20
NZ742241A (en) 2019-08-30
ZA201502310B (en) 2019-09-25
EP2895187A4 (en) 2015-12-02
US20170216396A1 (en) 2017-08-03
MX2015003164A (es) 2015-12-16
SG11201506113WA (en) 2015-09-29
IL237652B (en) 2020-06-30
BR112015005400A2 (pt) 2017-07-04
US20180177843A1 (en) 2018-06-28
SA515360129B1 (ar) 2016-08-15
HK1207006A1 (en) 2016-01-22
NZ706286A (en) 2018-05-25
ES2552754T1 (es) 2015-12-02
HUE13837694T1 (hu) 2016-04-28
AU2018217322A1 (en) 2018-09-06
CL2015000608A1 (es) 2015-11-06
US9655946B2 (en) 2017-05-23
EP4066849A1 (en) 2022-10-05
CA2884484A1 (en) 2014-03-20
TN2015000090A1 (en) 2016-06-29
IL237652A0 (en) 2015-04-30
DE13837694T1 (de) 2015-12-31
DK2895187T1 (da) 2015-11-16
EP2895187A1 (en) 2015-07-22
AU2018217322B2 (en) 2020-08-27
CY2200004T2 (el) 2016-02-10
US20150313958A1 (en) 2015-11-05
CA2884484C (en) 2021-01-19
US20200237858A1 (en) 2020-07-30
US10357535B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
TN2015000090A1 (en) Daptomycin formulations and uses thereof
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
MY188541A (en) Besifloxacin for the treatment of resistant acne
WO2014052836A3 (en) Methods and compositions for treating infection
NZ702744A (en) D-amino acid compounds for liver disease
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
PH12018500071B1 (en) Plinabulin compositions
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
GB2518813A (en) OMV vaccine against Burkholderia infections
UA115357C2 (uk) Похідні піридин-4-ілу
PH12015501088A1 (en) Dimeric compounds
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
IN2013MU03216A (es)
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
MA37956A1 (fr) Formulations de daptomycine et leurs utilisations
MY171941A (en) Pharmaceutical compositions
UA83604U (en) Pharmaceutical composition
UA76716U (uk) 5,7-ДИМЕТИЛ-2-ОКСО-6-ФЕНІЛАЗО-ТІАЗОЛО[4,5-b]ПІРИДИН-3-ІЛГІДРАЗОНИ АЦЕТАТНОЇ КИСЛОТИ, ЩО ПРОЯВЛЯЮТЬ АНТИЕКСУДАТИВНУ ДІЮ

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration